Search

Displaying results 2531 - 2540 of 10000 in total
  1. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  2. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.

  3. Drug

    Fludrocortisone

    go.drugbank.com/drugs/DB00687
    ApprovedInvestigational

    Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.

  4. Drug

    Lactose

    go.drugbank.com/drugs/DB04465
    ApprovedInvestigationalWithdrawn

    A disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.

  6. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

  7. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa … Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label].

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.

  9. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx.

  10. Drug

    Pomalidomide

    go.drugbank.com/drugs/DB08910
    ApprovedInvestigational

    Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.